Market Report, "Netherlands Pharmaceuticals & Healthcare Report Q3 2013", Published
We continue to expect yet another year of pharmaceutical market value contraction in the Netherlands. Having been valued at EUR6.56bn (US$8.33bn) at consumer prices in 2012, or US$498 per capita, we expect negative pressures on volume consumption of medicines as well as on their prices to remain in play, especially as the government foots over 80% of the total healthcare bill. In combination with patent expirations, we expect such pressures to prevent the market's value growth from returning to the...
View full press release